Evidence map›Paper›PMID 28506229›Full record

ArticleAnnals of clinical microbiology and antimicrobials2017

Determinants of felt demand for dengue vaccines in the North Caribbean region of Colombia.

Yalil T Bracho-Churio, Ruth A Martínez-Vega, Alfonso J Rodriguez-Morales, Ronald G Díaz-Quijano, María L Luna-González, Fredi A Diaz-Quijano

Abstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yalil T Bracho-ChurioOrganización Latinoamericana para el Fomento de la Investigación en Salud, Bucaramanga, Santander, Colombia.
Ruth A Martínez-VegaOrganización Latinoamericana para el Fomento de la Investigación en Salud, Bucaramanga, Santander, Colombia.
Alfonso J Rodriguez-MoralesOrganización Latinoamericana para el Fomento de la Investigación en Salud, Bucaramanga, Santander, Colombia.
Ronald G Díaz-QuijanoOrganización Latinoamericana para el Fomento de la Investigación en Salud, Bucaramanga, Santander, Colombia.
María L Luna-GonzálezOrganización Latinoamericana para el Fomento de la Investigación en Salud, Bucaramanga, Santander, Colombia.
Fredi A Diaz-QuijanoDepartment of Epidemiology, Faculdade de Saúde Pública, Universidade de São Paulo, Av. Dr. Arnaldo, 715, São Paulo, SP, CEP-01246-904, Brazil. frediazq@msn.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing burden associated with dengue in Latin America makes it essential to understand the community's interest in acquiring vaccines, as an input to plan its introduction in endemic regions. The objective of this study is to learn the felt demand for dengue vaccines by estimating the willingness to pay and its associated factors in endemic communities of the North Caribbean region of Colombia.

methodsA population survey was administered from October to December 2015, including 1037 families in 11 municipalities in Colombia. One adult per family was interviewed on their perception and history of dengue. Participants received a description of four hypothetical scenarios of dengue vaccines, administered in a single dose or in 3 doses, with an effectiveness of 70% for 5 years or 95% for 30 years. The willingness to pay for each one of these vaccines was inquired vs. 5 hypothetical prices in Colombian pesos.

resultsMost participants recognized dengue as a serious disease in children (99.3%) and adults (98.6%). 33 (3.2%) of the total respondents reported having suffered dengue and 19 (57.6%) of them required hospitalization. The price of the vaccine was inversely related to the willingness to pay. In addition, single dose vaccines (compared to 3 doses) and one with a protection of 95% for 30 years (compared to an effectiveness of 70% for 5 years), were associated with greater willingness to pay. Greater willingness to pay was observed among the respondents who considered it likely to get the disease, either themselves (OR 1.56; CI 95% 1.08-2.26) or their children (OR 1.89; CI 95% 1.28-2.81), in the next 5 years. The participants who have been diagnosed with dengue also showed greater willingness to pay (OR 1.89; CI 95% 1.01-3.54) compared to those who did not have this history.

conclusionFactors such as price, number of doses and effectiveness can independently influence the decision to purchase a vaccine against an endemic disease, such as dengue. Additionally, this study reveals that background and perceptions of the disease can affect individuals' interest in acquiring this type of preventive interventions.

Indexed as

Health Knowledge, Attitudes, PracticeAdultCaribbean RegionCohort StudiesColombiaDengueDengue VaccinesFemaleHumansMaleMiddle AgedOdds RatioPatient Acceptance of Health CarePatient ParticipationRisk FactorsSurveys and QuestionnairesDengue Vaccines

Identifiers

PMID28506229
PMCPMC5432981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.